News

FDA advisory panel votes against Capricor's Duchenne cell therapy deramiocel

On 29 July 2026, a U.S. Food and Drug Administration advisory committee voted 9–3 that Capricor Therapeutics had not shown "substantial evidence" that its experimental cell therapy deramiocel is effective in treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) — the leading cause of death in the disease.

The Cellular, Tissue, and Gene Therapies Advisory Committee met to review Biologics License Application (BLA) 125842 for deramiocel (human allogeneic cardiosphere-derived cells). FDA reviewers had argued in briefing documents that the therapy missed the original goals of its Phase 3 HOPE-3 study and that the benefits Capricor reported leaned on a revised statistical analysis plan. Capricor countered that FDA staff relied on an older, irrelevant analysis and that its own plan was finalised before the study was unblinded.

As the meeting opened, full HOPE-3 results were published in The Lancet , reporting that deramiocel slowed skeletal-muscle weakening by 54% and heart dysfunction by 91% versus placebo in 106 patients with advanced DMD. The vote is non-binding; the FDA is expected to make its decision on Capricor's resubmission by 22 August 2026. The agency rejected an earlier version of the filing in July 2025.

More top stories